Clinical Trials Logo

Relapsed/Refractory AML clinical trials

View clinical trials related to Relapsed/Refractory AML.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05428969 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Start date: June 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

NCT ID: NCT05054543 Recruiting - Clinical trials for Relapsed/Refractory AML

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Start date: October 18, 2021
Phase: Phase 3
Study type: Interventional

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

NCT ID: NCT04839341 Recruiting - Clinical trials for Relapsed/Refractory AML

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Start date: February 24, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

NCT ID: NCT03631576 Recruiting - Clinical trials for Relapsed/Refractory AML

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Start date: August 10, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.